Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

1-1-2022

Is Botulinum Toxin Effective at Reducing Sensory Symptoms in
the Hands of Patients with Raynaud’s Phenomenon?
Maria C. DiCioccio
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Mental Disorders Commons, and the Physical Therapy Commons

Recommended Citation
DiCioccio, Maria C., "Is Botulinum Toxin Effective at Reducing Sensory Symptoms in the Hands of Patients
with Raynaud’s Phenomenon?" (2022). PCOM Physician Assistant Studies Student Scholarship. 641.
https://digitalcommons.pcom.edu/pa_systematic_reviews/641

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For
more information, please contact jaclynwe@pcom.edu.

Is Botulinum Toxin Effective at Reducing Sensory Symptoms in the
Hands of Patients with Raynaud’s Phenomenon?

Maria C. DiCioccio, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant

Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania

December 17, 2021

ABSTRACT
Objective: The objective of this systematic review is to determine, “Is Botulinum Toxin
Effective at Reducing Sensory Symptoms in the Hands of Patients with Raynaud’s
Phenomenon?”
Study Design: A systematic review of two randomized controlled trials (RCTs) and one
prospective case series published between 2017 and 2019.
Data Sources: The articles were discovered using PubMed or Academic Search Premier. The
articles were published in English in peer-reviewed journals and selected based on pertinence to
the clinical question.
Outcome Measured: A reduction in sensory symptoms was the outcome measured in all three
studies using the VAS pain score (0-10/100) or McCabe Cold Sensitivity Score (0-400).
Results: In the prospective case series led by Dhaliwal, VAS pain score decreased after postBtx-A treatment at 12-weeks, indicated by a mean change from baseline of 2 (p = 0.05). In the
RCT led by Bello, McCabe Cold Sensitivity Score decreased 39.6 points in the Btx-A group
after 4 months (p = 0.906). Additionally, VAS pain score reduced 1.44 points in the Btx-A group
after 4 months (p = 0.327). In the RCT led by Motegi, VAS pain score decreased in the Btx-B
group by 12 weeks, indicated by a mean change from baseline of 50% (p < 0.05).
Conclusion: Dhaliwal et al. and Motegi et al. provide statistically significant evidence that
botulinum toxin reduces sensory symptoms in patients with RP, however, Bello et al. does not
support this hypothesis. It cannot be determined whether botulinum toxin improves sensory
symptoms in patients with RP.
Key Words: Raynauds, botox
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INTRODUCTION
Raynaud’s phenomenon (RP) is a sudden, exaggerated spasm of the digital arterioles to
cold temperatures or emotional stress. A true diagnosis of RP includes color changes of the
hands or feet (sometimes even the ears or nose), in addition to discomfort or extreme pain. There
are two types of RP, primary, also known as Raynauds disease, or secondary. Both types of RP
mainly affect women compared to men. Primary RP is idiopathic and typically presents between
the ages 15 and 30. Secondary RP predominantly develops in patients with another illness, most
commonly being connective tissue diseases like systemic sclerosis (scleroderma) or lupus. This
type of RP tends to occur in patients over the age of 30 and is generally more severe, leading to
complications including ulcers and gangrene.1 Up to 5% of the general population has
Raynaud’s.2 The total healthcare cost of RP is unknown, but the first-line pharmacologic
treatment for RP is nifedipine, a calcium channel blocker that can range from $75-200 per
month.3 Additionally, for severe cases, PDE5 inhibitors like sildenafil can be used, costing about
$826 per month.3,4 The exact number of healthcare visits for RP each year is unclear, however,
high volume of physician services is used for secondary RP, involving patients with systemic
sclerosis, Sjogren’s syndrome, rheumatoid arthritis, or lupus.5
The underlying cause of RP is still under investigation, however, it is a vasospasm of the
digits in response to cold temperatures, stress, or other physical or medical exposures.3 The
initial color change is white or pallor due to vasoconstriction, then it changes to blue or cyanotic
due to deoxygenation, and lastly red because of vasodilation/reperfusion. Primary RP tends to be
more symmetric, episodic, and without evidence of peripheral vascular disease. Secondary RP is
more frequent, painful, asymmetric, and can lead to digital ulcerations.3 Treatment for RP
depends on its severity. Less severe symptoms may be treated with diet and lifestyle
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modifications. Avoidance of cold stimuli, tobacco, and sympathomimetics, as well as reducing
stress, exercising more, and wearing mittens and hats, are some non-pharmacologic options.
Pharmacotherapy can be utilized for more symptomatic RP, and these medications include
calcium channel blockers, angiotensin II receptor blockers, topical nitrates, phosphodiesterase
inhibitors, SSRIs, statins, endothelin-receptor inhibitors, and IV prostacyclin or prostacyclin
analogs. Refractory or severe cases like digital ischemia and ulcers are indications for surgery,
with a procedure called digital artery sympathectomy.2
Calcium channel blockers (CCBs) work by causing vasodilation, thus reducing
vasospasm in the arterioles. CCBs are confirmed to reduce the frequency, duration, severity of
attacks, pain and disability associated with RP, however, nifedipine can have adverse side
effects, including headache, flushing, constipation, fatigue, and peripheral edema.4 Nifedipine,
along with other pharmacologic agents may fail to improve symptoms in those with secondary
RP, and thus surgery serves as a last-line therapy for these patients. A new, non-invasive
alternative for unmanageable RP is botulinum toxin injection. Proposed mechanisms of
botulinum toxin include inhibition of sympathetic adrenergic or cholinergic vasoconstriction and
inhibition of sensory nerves, thus providing symptomatic relief.6 This paper evaluates two
randomized control trials (RCTs) and one prospective case series, assessing the efficacy of
botulinum toxin as a treatment for Raynaud’s phenomenon.
OBJECTIVE
The objective of this selective EBM review is to determine, “Is Botulinum Toxin
Effective at Reducing Sensory Symptoms in the Hands of Patients with Raynaud’s
Phenomenon?”
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METHODS
Studies were selected based on validity, pertinence to the clinical question regarding
botulinum toxin as a treatment for RP, and incorporation of patient-oriented outcomes,
specifically sensory symptoms. Inclusion criteria was articles of English language published in
2010 or later. Exclusion criteria was articles published before 2010, non-English language, and
systematic reviews. The articles were discovered via PubMed and Academic Search Premier
using the words “Raynauds” and “botox”.
The population targeted for this review was individuals with Raynauds phenomenon. The
demographics and characteristics of these studies is included in Table 1. The intervention being
investigated for sensory symptom reduction for RP is botulinum toxin A or B hand injection.
Bello et al. used between-arm control and Botox A injection groups. Dhaliwal et al. compared
pre- and post-Botox A injections at 12 weeks. Lastly, Motegi compared Botox B injections with
a control group of no treatment. The outcomes measured were pain and cold sensitivity using
VAS pain score and McCabe Cold Sensitivity Score, respectively. A summary of statistics
reported includes p-values and mean change from baseline. The studies involved in this EBM
review include a double-blind RCT, single-blind RCT, and prospective case series.
OUTCOME MEASURED
All three studies utilized the VAS (visual analog scale) pain score, a 0-100 mm or 0-10
cm scale that subjectively measures acute and chronic pain (0 = no pain, 100/10 = worst
pain).5,6,7 In addition to VAS score, Bello et al. utilized the McCabe Cold Sensitivity Score (0400) to measure cold sensitivity in the hands of patients with RP.6
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Table 1. Demographics & Characteristics of Included Studies
Study

Type

Dhaliwal
5 (2019)

Prospect
ive case
series

Bello6
(2017)

RCT

Motegi7
(2017)

RCT

# Age
Inclusion
Pts (yrs
Criteria
)
40 25- Female patients
76
were chosen with
RP secondary to
systemic sclerosis,
a diagnosis criteria
met by the ACR.
None of the
patients were
smokers.
40 21- Patients with
75
bilateral RP and
scleroderma
diagnosis criteria
met by the ACR.
Patients also have
at least 3 of 5
features of CREST
syndrome, or had
definite RP,
abnormal nailfold
capillaries, and a
sclerodermaspecific
autoantibody.

9

5565

Patients with RP
secondary to
systemic sclerosis
met by the
American College
of Rheumatology
(ACR). Patients all
have a history of
severe RP and
have taken oral
prostanoids,
beraprost sodium,
and/or antiplatelet
agents.

Exclusion
Criteria
Active
infections, acute
digital ischemia,
allergies to
botox, pregnant
or lactating.

W/D

0

Active hand
0
infection in
either hand,
acute digital
ischemia,
myasthenia
gravis, allergies
to botox,
previously
received botox,
previous upper
extremity
vascular surgery,
receiving
aminoglycoside
antibiotics, or
pregnant or
lactating.
Patients under 18 Not
years old,
addressed.
pregnant, and
previously
treated with
BTX-B.

Interventi
ons
PreBTX-A
100 inj.
vs 12week
post inj.

BTX-A
50 U
experime
ntal hand
vs. 2.5 ml
sterile
saline
control
hand

BTX-B
250 U
group vs.
no
treatment
control
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RESULTS
Dhaliwal et al. conducted a prospective case series on 40 female patients with RP
secondary to scleroderma at the Royal Free Hospital between March 2015 and February 2016.
Inclusion and exclusion criteria for selection of these patients can be found in Table 1. Of these
40 patients, 20 had diffuse scleroderma and 20 had limited scleroderma, with an average duration
of disease of 15 years. Patient consent was obtained, and medications were continued throughout
the study, including calcium channel blockers, iloprost, fluoxetine, PDE-5 inhibitors, and
losartan. All patients were treated with 100 units of Btx-A, reconstituted with 2 ml of normal
saline, across both hands in a dorsal fashion around the digital neurovascular bundles of all five
digits. VAS pain scores (0-10 cm) in Pre-Btx-A and 12-week Post-Btx-A were compared. There
were no adverse effects noted throughout the 12 weeks, other than injection site pain lasting 4
days in one patient and itching for the first 2 days in another patient. All participants were
accounted for and attributed at its conclusion.5
As noted in Table 2, VAS pain score in pre-Btx-A was 5 and in 12-week post-Btx-A was
3, resulting in a mean change from baseline of 2 (p = 0.05). A p-value < 0.05 indicates statistical
significance.5
Table 2. VAS Pain Score from Baseline to 12 Weeks Post Injection

VAS Score

Baseline

12 weeks

5

3

Mean Change
from Baseline
2

P-value
0.05

Bello et al. selected 40 patients to participate in a randomized, double-blind, parallelgroup, placebo-controlled clinical trial at the Johns Hopkins Scleroderma Center in Baltimore,
MD, between January and September 2015. All patients had a diagnosis of scleroderma in
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addition to RP, with at least 3 of the 5 features of CREST syndrome according to the American
College of Rheumatology. Twenty-five of these patients had limited scleroderma and 15 had
diffuse scleroderma, with a median time of diagnosis of 14 years and median time since RP onset
of 15.6 years. Thirty-one patients were women and 9 were men, with a mean age of 51.9 ± 12.3
years. Most patients were treating RP with calcium-channel blockers at baseline. Patients were
selected based on specific inclusion and exclusion criteria listed in Table 1. Participants received
dorsal injections (similar method as Dhaliwal et al.) of 50 units of Btx-A, reconstituted in 2.5 ml
of sterile saline, in one randomly selected hand, and 2.5 ml of sterile saline in the opposite
control hand. The study pharmacists created a random sequence with blocks of 4 patients to
establish a treatment group allocation of 1:1 ratio, using Microsoft Excel 2007. Study
participants and all study team members, except for the study pharmacists, were blinded to
treatment allocation and size of randomization blocks. In-person study visits took place at 4
months post injection. VAS pain score (0-10 cm) and McCabe Cold Sensitivity Score were
reported for each hand of every patient. All subjects who entered the trial were accounted for and
attributed at its conclusion. Two participants (5%) experienced weakness of the intrinsic muscles
of the hand post Btx-A injections. These patients recovered by 3 and 9 weeks.6
Table 3 depicts the McCabe Cold Sensitivity Score from baseline to 4 months post
injection. A statistically significant difference was measured as a p-value ≤ 0.050. McCabe Cold
Sensitivity Score decreased 39.6 points in the Btx-A group after 4 months (p = 0.906). Btx-A
group was 0.31 points lower than the control group at the 4-month follow-up (p = 0.963). In the
Btx-A treatment group, there was a mean change in VAS pain score of 1.44, represented in Table
4. In the placebo group, there was a mean change of 1.83. The difference in mean change
between these group is indicated by a p-value of 0.327. VAS pain score in the experimental
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group was 0.15 cm higher than the control group after 4 months. The between-arm difference is
indicated by a p-value of 0.585.6
Table 3. McCabe Cold Sensitivity Score from Baseline to 4 Months Post Injection
Baseline

4 Months

Mean Change P-value
from Baseline

Btx-A

221.79

182.19

39.6

Placebo

221.15

182.5

38.65

0.906

Mean
difference
(calculated)
0.310

Table 4. VAS Pain Score from Baseline to 4 Months Post Injection
Baseline

4 Months

Btx-A

3.43

1.99

Mean Change P-value
from
Baseline
1.44
0.327

Placebo

3.67

1.84

1.83

Mean
difference
(calculated)
0.15

Motegi et al. conducted a prospective, single-blind (patients-blind), randomized trial on
45 scleroderma patients with RP over the winter months from 2015 to 2016 at the Department of
Dermatology, and Clinical Investigation and Research Unit, Gunma University in Japan. Of the
45 patients, there were 4 males and 41 females with a mean age of 60.7 ± 1.9 years. All patients
met the criteria for scleroderma proposed by the American College of Rheumatology. Inclusion
and exclusion criteria for selection of patients can be found in Table 1. Twenty-five patients had
limited cutaneous type and 20 had diffuse cutaneous type according to LeRoy et al.’s
classification.7 Patients were blinded and randomly selected using the Hope eACReSS system
(Fujitsu, Japan) for no-treatment control or treatment of 250 units of Btx-B injections per hand.
The hand with the most severe symptoms in each patient was chosen for injection, and 250 units
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of Btx was diluted in 2.25 ml saline. Of the 45 patients, only 9 were chosen to receive the 250
units of Btx-B, while the others either received no treatment, 1000 units of Btx-B, or 2,000 units
of Btx-B. Injections were performed on the palmar aspect of the hand, as opposed to Bello and
Dhaliwal’s dorsal approach. VAS pain score (range 0-100 mm) was utilized to assess pain
severity after 12 weeks post injection. Adverse events were reviewed at each visit, and none
were noted in the treatment group other than mild pain at the injection site that resolved within a
few hours. It is unclear whether all patients were accounted for and attributed at its conclusion.7
As depicted in Table 5, baseline VAS pain score in the 250-unit Btx-B group was 100%,
and at 12 weeks the value decreased to 50%, resulting in a mean change of 50%. On the other
hand, control group increased by 25% from baseline. A statistically significant value is indicated
by a p-value < 0.05. The mean difference from baseline between these groups was given a pvalue < 0.05.7
Table 5. VAS Pain Score from Baseline to 12 Weeks Post Injection
Baseline

12 Weeks

Mean Change
from Baseline

P-value

Btx-B

100

50

-50%

<0.05

Placebo

100

125

+25%

Mean
difference
(calculated)
75

DISCUSSION
Raynaud’s Phenomenon is a debilitating condition, especially for patients with
scleroderma. Pharmacological treatments can fail to alleviate symptoms, resulting in ischemia,
ulcers, and gangrene, and surgical procedures can lead to severe complications. Botulinum toxin
can serve as a non-surgical treatment option for refractory RP. Although rare, there are some
complications or side effects that can accompany botulinum toxin. Local side effects include
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pain at injection site, ecchymosis, or intrinsic muscle weakness; these effects have proven to be
transient in the previous studies discussed. Some systemic complications include nausea, fatigue,
flu-like symptoms, diplopia, dysarthria, ptosis, dysphagia, dystonia, urinary incontinence, and
rashes.8 Evidently, these effects are more likely to arise following palmar injections.7
This systematic review focuses on the effectiveness of botulinum toxin as a non-invasive
alternative therapy for reducing sensory symptoms in the hands of patients with RP. Bello et al.
did not provide significant results in McCabe Cold Sensitivity Score or VAS pain score between
the hands of Btx-A injection and placebo (p = 906 and 0.327, respectively).6 Although both
scores did decrease after 4 months, the reduction was not significant compared to the control
group. On the other hand, Motegi et al. demonstrated significant VAS pain scores in patients
treated with 250 units of Btx-B after 12 weeks compared to the control (p < 0.050).7 This study
shows the effectiveness of Btx-B as a treatment option for pain reduction in RP, proposing that
Btx-B accomplishes this through blockage of noradrenaline release, which prevents spasms and
vascular contraction. Dhaliwal et al. also demonstrated a significant mean change in VAS pain
scores from baseline to 12 weeks (p = 0.050).5
One limitation within the studies is the number of participants. In Motegi et al., the target
group consisted of only 9 participants, whereas Bello et al. and Dhaliwal et al. incorporated 40
patients.5,6,7 Overall, it would be more beneficial to have a greater sample size within all three
studies, providing a more effective representation of the general population. Additionally, types
of medications and their dosages prior to treatment vary between the studies, possibly reducing
the validity of the results. For example, in Dhaliwal et al., all patients continued their normal
medications for RP throughout the study, including calcium channel blockers, iloprost,
fluoxetine, PDE-5 inhibitors, and losartan.5 The length of experiments differ as well. Motegi and
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Dhaliwal obtained results at 12 weeks, and Bello gathered information at 4 months (16
weeks).5,6,7 In the 4-month experiment, botulinum toxin may have worn off in these patients.
A limitation of my own research is the absence of studies on patients with primary RP, as
all three of my studies focused on patients with secondary RP. Although patients with primary
and secondary RP can differ in severity of their condition and response to treatment, broadening
my research to both subsets of RP would expand the generalizability of this systematic review,
however, this may sacrifice the precision. Additionally, my results may have been more precise
if I solely targeted Btx-A or Btx-B, as there are discrepancies between the two forms of
botulinum toxin. Motegi et al. addresses that several clinical studies have proven Btx-B to have a
quicker onset of action compared to Btx-A, and furthermore, has a more beneficial effect in
treating diseases regulated by the autonomic nervous system.7 With regards to data comparison,
all three studies use different amounts of botulinum for their intervention, and although Motegi
splits interventions into 4 sets, I focused on the intervention that was most like the other two
studies. This resulted in a target group of only 9 patients receiving 250 units in Motegi’s study.7
Another limiting factor in my selection of journals is that all three studies contain slightly
different injection techniques or approaches. Dhaliwal and Bello et al. use dorsal approaches, and
in Dhaliwal et al, the author discusses, “Two injections per web space are needed and the
injection must be deep feeling the proximal phalanx bone as you inject.”5,6
CONCLUSION
In this systematic review, Dhaliwal et al. and Motegi et al. provide statistically significant
evidence that botulinum toxin reduces sensory symptoms in patients with RP, however, Bello et
al. does not demonstrate statistical significance, and therefore, does not support this hypothesis.
Based on these outcomes, it cannot be determined whether botulinum toxin improves sensory
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symptoms in patients with RP. Although the VAS pain scores significantly decreased compared
to the control groups in Motegi et al. and Dhaliwal et al., Bello et al. is the only randomized,
double-blind, controlled study, and therefore, is the highest quality study and most reliable to
draw a conclusion.
Some considerations are important to take note of with regards to future research studies
on botulinum toxin and RP. Larger sample sizes should be implemented in future studies, as this
reduces the chance that data will be skewed due to outliers. Also, patients with RP secondary to
scleroderma should be selected and compared based on duration of disease, as Bello et al.
showed a better response in patients with limited scleroderma and earlier RP (shorter time since
RP onset).6 Future studies should focus on patients with similar medication regimens prior to
treatment. Furthermore, these studies should continue the same medications and dosages for
every patient or discontinue all medications prior to treatment, in addition to addressing this
factor within the study. Lastly, more randomized, double-blind, placebo-controlled studies like
Bello et al. should be performed in the future, as this study has served as a basis for future
research. More double-blinded RCT studies are imperative to clearly understand the mechanism
at which botulinum toxin functions, as well as the best approach in its administration, to improve
the quality of life among patients living with Raynaud’s Phenomenon.
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